BTK and COVID-19: Ibrutinib is a pyrazolopyrimidine and a member of the acrylamides, and serves as an oral inhibitor of BTK that is used in the therapy of refractory chronic lymphocytic leukemia and mantle cell lymphoma.509,510 Treon et al. demonstrated that it may provide protection against lung injury and even improve pulmonary function in hypoxic patients with COVID-19.234 Five of the six COVID-19 patients receiving ibrutinib for Waldenstrom macroglobulinemia showed a steady improvement and resolution of COVID-19-related symptoms.